{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-23-001396","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.083223+00:00","generated_at":"2026-06-15T08:15:29.317666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Standard BioTools Q1 core revenue up 1.8% YoY; operating cash burn cut 55.8% sequentially","bullets":["GAAP revenue $25.1M (-5.2% YoY); core product/service revenue $24.3M (+1.8% YoY).","GAAP product margin 46.6% (+567 bps QoQ); non-GAAP margin 60.9% (+792 bps QoQ).","Operating cash burn $8.5M, down from $19.2M in Q4 2022 and $15.6M in Q1 2022.","Launched Hyperion XTi Imaging System; subleased 50% of SSF space; repurchased 1.3M shares for $2.5M.","FY2023 guidance: flat-to-moderate core revenue growth; GAAP opex $118-123M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-23-001396","json":"https://secwatch.observer/filing/0000950142-23-001396.json","markdown":"https://secwatch.observer/filing/0000950142-23-001396.md","text":"https://secwatch.observer/filing/0000950142-23-001396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/0000950142-23-001396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/eh230357220_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:15:29.317666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37420c90bc0002cfb056dad6c78f4dd662307938","claim":"STANDARD BIOTOOLS INC. reported first quarter ended March 31, 2023 results: revenue $25.1 million.","evidence_excerpt":"in the fourth quarter and a 46% reduction from the $15.6 in the first quarter last year GAAP revenue (includes discontinued/COVID-19 products) decreased 5.2% year-over-year to $25.1 million, with a 1.8% year-over-year increase in ongoing, core product and service revenue to $24.3 million GAAP product and services margin of 46.6%, an improvement of 567 basis points","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/0000950142-23-001396-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$25.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}